Dr. Navneet Majhail, M.D., M.S., Director, Blood and Marrow Transplant Program, Cleveland Clinic, and an Incyte Ingenuity Award judge discusses the Incyte Ingenuity Award Program which was created to support people impacted by graft-versus-host disease (GVHD). This condition can occur after an allogeneic stem cell transplant where the donated cells initiate an immune response and attack the transplant recipient’s organs, leading to significant morbidity and mortality. The 2021 Incyte Ingenuity Award program has been expanded to now include a second $35,000 award in addition to the original $100,000 award to better support projects of different scales. Open for entries until June 30, 2021.
Navneet Majhail, MBBS, MD, MS. Dr. Navneet Majhail is the Director of the Blood & Marrow Transplant Program at the Taussig Cancer Institute, Cleveland Clinic, and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio. He has also previously served as President of the American Society for Transplantation and Cellular Therapy. Dr. Majhail specializes in the care of adult patients receiving blood and marrow transplantation. His research focuses on transplant outcomes, health services and health policy issues in blood and marrow transplantation, and quality of life and late effects in transplant survivors, including patients with graft-versus-host disease. His research has been funded by the Patient Centered Outcomes Research Institute and the National Institutes of Health.